KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Interest & Investment Income (2023 - 2025)

Biocryst Pharmaceuticals (BCRX) has disclosed Interest & Investment Income for 9 consecutive years, with $2.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Interest & Investment Income fell 19.05% year-over-year to $2.9 million, compared with a TTM value of $10.7 million through Dec 2025, down 27.65%, and an annual FY2025 reading of $10.7 million, down 27.65% over the prior year.
  • Interest & Investment Income was $2.9 million for Q4 2025 at Biocryst Pharmaceuticals, up from $2.2 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $15.4 million in Q4 2023 and bottomed at $2.2 million in Q3 2025.
  • Average Interest & Investment Income over 3 years is $4.5 million, with a median of $3.6 million recorded in 2024.
  • The sharpest move saw Interest & Investment Income tumbled 76.83% in 2024, then dropped 19.05% in 2025.
  • Year by year, Interest & Investment Income stood at $15.4 million in 2023, then crashed by 76.83% to $3.6 million in 2024, then decreased by 19.05% to $2.9 million in 2025.
  • Business Quant data shows Interest & Investment Income for BCRX at $2.9 million in Q4 2025, $2.2 million in Q3 2025, and $2.5 million in Q2 2025.